rankl/rank

Amakusamine is an indole alkaloid from the sponge of Psammocinia sp. It inhibits RANKL-induced isolation of multinucleated osteoclasts and inhibits RANKL-induced multinucleated osteoclasts.

Pamidronate Disodium (CGP 23339A), a nitrogen-containing bisphosphonate, can help to strengthen bones.

Pamidronate disodium pentahydrate is a bone resorption inhibitor, a compound capable of preventing osteoporosis.

10-Hydroxydecanoic Acid (NSC 15139) has antibacterial, anti - cancer and anti - radiation activity.

Cyanidin Chloride, the main phenolic antioxidant in the grape (Vitis vinifera), in particular in the liposomal forms, could be used for treatment of diabetes mellitus complications.

Boldine (1,10-Dimethoxy-2,9-dihydroxyaporphine) is a natual product .Boldine displays anti-cancer, cytoprotective , anti-oxidant and anti-inflammatory activities.

Alisol B may be a potential novel therapeutic molecule for bone disorders through targeting the differentiation of osteoclasts as well as their functions. Alisol B also inhibited RANKL-induced expression of NFATc1 and c-Fos, which are key transcription factors for osteoclastogenesis.

Narlumosbart (JMT103) is an IgG4κ monoclonal antibody that selectively binds to the receptor activator of nuclear factor-κB ligand (RANKL)[1].

Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand

Phlorigidoside C is a natural cycloartenol glycoside isolated from the Tibetan medicinal plant Lamiophlomis rotata that exerts anti-rheumatoid arthritis (RA) effects by modulating the OPG/RANKL/NF-κB pathway.

Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.

AS2690168 freebase is an orally active inhibitor of RANKL signaling, capable of suppressing RANKL-induced osteoclastogenesis in RAW264 cells. AS2690168 is applicable in research related to pathological bone resorption.

SPA0355 is a thiourea derivative with antioxidant and anti-inflammatory properties. It inhibits RANKL (receptor activator of nuclear factor κB ligand)-induced osteoclastogenesis in primary bone marrow-derived macrophages and suppresses the activation of MAPKs, Akt, and NF-κB pathways. Furthermore, SPA0355 enhances osteoblast differentiation by increasing alkaline phosphatase activity and mineralized nodule formation. It protects ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it a potential candidate for studying postmenopausal osteoporosis.

AS2690168 hydrochloride is an orally active inhibitor of RANKL signaling that can suppress RANKL-induced osteoclastogenesis in RAW264 cells. AS2690168 is applicable in research related to pathological bone resorption.

RANKL-IN-1 is a selective inhibitor of receptor activator of nuclear factor-κB ligand (RANKL), with a KD value of 7.6 μM. It shows inhibitory activity and selectivity in osteoclastogenesis, with an IC50 of 0.07 μM and a selectivity index (SI) of 82.57. By directly binding to RANKL, RANKL-IN-1 blocks the activation of RANKL-induced NF-κB and MAPK pathways. This compound is applicable in research on metabolic diseases such as osteoporosis.

Bisnoralcohol, an RANKL inhibitor, has an IC50 value of 2.325 μM. It effectively suppresses RANKL-induced osteoclastogenesis and exhibits anti-osteoporotic activity.

Pamidronic acid Leads to Bone Necrosis via Suppression of Wnt/β-Catenin Signaling in Human Bone Marrow Mesenchymal Stem Cells

Anti-MouseRANKL/CD254Antibody (IK22/5) is a rat-derived IgG2a, κ antibody inhibitor targeting the mouse RANKL/CD254.

Anti-RANKL Antibody (4B810) is a Rabbit IgG monoclonal antibody targeting Human RANKL.

(2S)-2'-Methoxykurarinone is isolated from the roots of Sophora flavescens. (2S)-2'-Methoxykurarinone has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone displays cytotoxic activity against human myeloid leukemia HL-60 cells.

NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1].

PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.

Anti-osteoporosis agent-8 (Compound 4aa) is a RANKL inhibitor, capable of preventing RANKL-induced osteoclastogenesis and osteoclast differentiation, with an IC50 of 2.41 μM. Furthermore, Anti-osteoporosis agent-8 has been shown to mitigate bone loss in an ovariectomized (OVX) mouse model.

Y2641, a tetrahydro β-carboline derivative, is an orally active dual inhibitor of RANKL and TNF-α, with Kd values of 3.984 μM and 18.59 μM respectively. It suppresses RANKL-induced osteoclastogenesis and exhibits anti-inflammatory and cartilage-protective properties. Y2641 is applicable in osteoarthritis research.